NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

FONAR Corporation (FONR) Stock Analysis

FONAR Corporation (FONR) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

FONR

$19.09

+$0.18 (+0.95%)

Last trade June 3, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FONR with… →

FONR Key Statistics

As of Jun 3, 2026
Trading
Open
$19.09
Previous Close
$18.91
52-Week Range
13.62–18.95
Valuation
Market Cap
$119.06M
P/E Ratio
18.91
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.13
EPS (ttm)Profit attributable to each share over the last twelve months.
1.00
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
6.35%
1-Year Return
+31.47%
Dividend and dates
Avg Volume
51.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FONR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+2.86%
2025+22.59%
2024 (partial year)+0.20%

As of June 3, 2026.

FONR Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricFONRDiagnostics & Research medianvs median
P/E18.9133.0843% below
P/S ratio1.134.990.2x the median
Profit margin6.35%0.00%6.4 pts above

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values FONAR Corporation (FONR) at $119.06M. It is classified in the Diagnostics & Research industry, within the Healthcare sector. The company reports 535 employees.

The most recent close on file for FONR is $19.09, dated June 3, 2026. That is +$0.18 (+0.95%) against the previous close. Over the past 52 weeks the price has ranged from $13.62 to $18.95. The latest close sits 40.16% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $105.34M. Profit margin runs at 6.35%. That is 6.4 percentage points above the Diagnostics & Research median of 0%. Trailing earnings per share are 1.

Valuation Assessment

The trailing P/E ratio stands at 18.91. That is 42.84% below the Diagnostics & Research median of 33.08. Measured against sales, the shares trade at 1.13 times revenue. On price-to-sales that is 0.2 times the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +31.47%. Daily returns over the trailing 1 year annualize to a volatility of 33%.

Growth & Income

The record shows no dividend for FONR.

The record holds one complete calendar year, 2025, which returned +22.59%. 2026 is still running; the price is +2.86% year to date.

Peer Comparison

FONAR Corporation (FONR) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
FONAR Corporation FONR $119.06M 18.9
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. FONAR Corporation trades at a P/E of 18.9.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of June 3, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About FONAR Corporation

FONAR Corporation, together with its subsidiaries, engages in the designing, manufacturing, selling, and servicing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries in the United States. It operates in two segments: Medical Equipment, and Physician Management and Diagnostic Services. The company offers an Upright MRI scanner, which allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. It also provides non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with legal and regulatory matters, and development and implementation of practice growth and marketing strategies. In addition, the company owns and operates diagnostic imaging facilities. The company markets its scanners to private diagnostic imaging centers and hospital outpatient imaging facilities. FONAR Corporation was founded in 1978 and is based in Melville, New York.

Visit website →